This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT06323161 |
|---|---|
| Status | Completed |
| Phase | Phase 3 |
| Sponsor | Novo Nordisk A/S |
| Enrollment | 274 participants |
| Design | Interventional, Randomized, Parallel, Masking: Quadruple |
| Conditions | Type 2 Diabetes |
| Interventions | Cagrilintide; Semaglutide; Placebo |
| Start | Mar 26, 2024 |
| Primary completion | Sep 9, 2025 |
| Study completion | Oct 23, 2025 |
| Results posted | Not yet |
| Registry last updated | Sep 9, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
This study will look at how much CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participant will get either CagriSema or "dummy" medicine and which treatment they get is decided by chance. Participant will take the study medicine together with their current diabetes medicine (once-daily insulin with or without metformin). For each participant, the study will last for about one year.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Change in Glycated Haemoglobin (HbA1c) | From baseline (week 0) to end of treatment (week 40) |
31 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
